Self-Study 2026: Utilization of Minimal Residual Disease (MRD) in Oncology

Type: Individual•Format: On-demand

In the evolving field of oncology treatment, there is a desire to optimize and establish more clarity for treatment duration, early detection, and relapse/surveillance. Once MRD testing becomes standardized and universally implemented, this could be the capstone of oncology treatment. MRD testing has become a key tool for impacting patient care and building comprehensive treatment plans within the oncology field. Historical data ties the use of MRD-like testing as early as 1970s. Given its ability to be tumor agnostic, MRD testing has the benefits of being both predictive and prognostic across different disease states.

This module will explore the evolution, current relevance, and challenges of MRD testing beyond biomarker-directed therapeutic agents.

Utilization of Minimal Residual Disease (MRD) in Oncology

Author: Jessica Zhao, PharmD, BCOP - Clinical Pharmacist Specialist, Malignant Hematology

Learning Objectives

  1. Define minimal residual disease (MRD)
  2. Describe the evolution of MRD and its relevance
  3. Assess the prognostic and predictive impact of MRD testing relative to treatment decisions
  4. Describe ongoing developments and approaches for MRD testing through current clinical trials and drug development

Get it here

Knowledge Course for Pharmacists

Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

acpe-bps-logos

HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.

All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.